Pharmaceuticals 2017, 10(1), 18; https://doi.org/10.3390/ph10010018
CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target
Melissa M.J. Chua †
, Charina E. Ortega †, Ayesha Sheikh, Migi Lee, Hussein Abdul-Rassoul, Kevan L. Hartshorn and Isabel Dominguez *
, Charina E. Ortega †, Ayesha Sheikh, Migi Lee, Hussein Abdul-Rassoul, Kevan L. Hartshorn and Isabel Dominguez *
Department of Medicine, School of Medicine, Boston University, Boston, MA 02118, USA
†
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Marc Le Borgne
Received: 2 December 2016 / Revised: 23 January 2017 / Accepted: 23 January 2017 / Published: 28 January 2017
(This article belongs to the Special Issue An Updated View on an Emerging Target: Selected Papers from the 8th International Conference on Protein Kinase CK2)
Abstract
CK2 genes are overexpressed in many human cancers, and most often overexpression is associated with worse prognosis. Site-specific expression in mice leads to cancer development (e.g., breast, lymphoma) indicating the oncogenic nature of CK2. CK2 is involved in many key aspects of cancer including inhibition of apoptosis, modulation of signaling pathways, DNA damage response, and cell cycle regulation. A number of CK2 inhibitors are now available and have been shown to have activity against various cancers in vitro and in pre-clinical models. Some of these inhibitors are now undergoing exploration in clinical trials as well. In this review, we will examine some of the major cancers in which CK2 inhibition has promise based on in vitro and pre-clinical studies, the proposed cellular and signaling mechanisms of anti-cancer activity by CK2 inhibitors, and the current or recent clinical trials using CK2 inhibitors. View Full-TextKeywords:
CK2; cancer; proliferation; apoptosis; migration; invasion; signaling pathways; signaling cascades; preclinical models; clinical trials; therapy
▼
Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Chua, M.M.; Ortega, C.E.; Sheikh, A.; Lee, M.; Abdul-Rassoul, H.; Hartshorn, K.L.; Dominguez, I. CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target. Pharmaceuticals 2017, 10, 18.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Related Articles
Article Metrics
Comments
[Return to top]
Pharmaceuticals
EISSN 1424-8247
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert